Related Experiment Video

Updated: Mar 13, 2026

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke
08:53

Randomized, Triple-Blind, and Parallel-Controlled Trial of Transcranial Direct Current Stimulation for Cognitive Rehabilitation after Stroke

Published on: June 6, 2025

2.0K

Improvement in Neurocognitive Manifestations with Short-term Multidisciplinary Intervention in DiGeorge Syndrome

Samir Dalwai1, Elyska DeSa, Deepti Kanade Modak

  • 1Department of *Pediatrics, #Psychology and $Public Health, New Horizons Health and Research Foundation, Saira Mansion, Jay Prakash Nagar, Goregaon East, Mumbai, India. Correspondence to: Dr Samir Dalwai, Director, New Horizons Health and Research Foundation, Saira Mansion, JP Nagar, Goregaon (E), Mumbai, India samyrdalwai@enablemychild.org.

Indian Pediatrics
|October 25, 2016
PubMed
Abstract

More Related Videos

The Dig Task: A Simple Scent Discrimination Reveals Deficits Following Frontal Brain Damage11:16

The Dig Task: A Simple Scent Discrimination Reveals Deficits Following Frontal Brain Damage

Published on: January 4, 2013

14.1K
Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE06:04

Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE

Published on: August 16, 2024

1.7K

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K